Featured
Meet the Best Drugs of 2026
A drug currently seeking to unlock broader government subsidy in Australia was crowned one of the best products of 2026 at the Prix Galien USA awards
Pipeline & Intellectual Property
Aussies find new combo to tackle deadly cancer
After this drug wowed ESMO last month Australian researchers have discovered another combo that could disrupt treatment for small cell lung cancer
Industry & Companies
AZ shuffles jobs to prep huge pipeline
The UK pharma giant has announced a "reshaping" programme which will see jobs lost in some areas but gained in others
Regulatory & Reimbursement
Aussie study applauds new-gen Novartis drug
South Australian researchers have described one of Novartis' fastest-growing brands as "a huge step forward" in frontline treatment options
Pipeline & Intellectual Property
Qld radiopharma defends manufacturing process
AdvanCell has challenged two patent application by a Norwegian company that cover the production of the radioisotope used in its flagship product
Regulation & Legal
Federal Court slaps company with $6.5M fine
TGA wins its case against a company which unlawfully advertised prescription-only medicines, which the judge described as a "deliberate commercial strategy"
Leadership & People
Ex-Novartis GM snapped up for global role
So that's where he's gone... Well-known Aussie pharma exec has been tapped for a global position, joining a new company at a time of significant growth
Regulatory & Reimbursement
Who nabbed half the November PBS listings?
Eight drugs won reimbursement over the weekend, with half of the medicines belonging to one pharma
Government & Policy
AbbVie pitches a world-class PBS
As concerns grow over Australia’s lagging access to medicines, AbbVie has released a report exposing just how far the country has fallen behind and who is paying the price
Regulatory & Reimbursement
Three pharmas hit with first rival
The TGA has approved the first copycats of long-standing drugs sponsored by Bayer, Link Medical Products, and Novo in Australia
Regulatory & Reimbursement
Aussies continue FDA winning streak
Melbourne-based pharma notches another win in the US with the granting of an Orphan Drug designation, marking an important commercial milestone
Featured
Out-of-pocket obesity drugs drives Lilly profits
Company rockets past analyst predictions thanks to a booming private market for its weight loss medications, smashing forecasts for the third quarter running
Regulatory & Reimbursement
Is the era of rising drug prices over?
The prices of new drugs at launch rose by over a third from 2022 to 2025, but the trend came to an abrupt end in the last year. Is this the start of a new era?
Government & Policy
Guild turns up heat on PBS prices
New poll puts pressure on Govt to freeze the PBS co-pay at $25 amid a cost-of-living crisis, just a couple of months out from a scheduled price hike
Latest
Health leaders of tomorrow start here
AbbVie helps inspire the next generation of changemakers by backing the Future Health Leaders Program alongside Research Australia and the CSIRO
Patients
Patients pick favourite pharma
One company shot up the rankings by four places to be declared the top Big Pharma when it comes to corporate reputation, judged by diabetes patients
Government & Policy
Biologics finally move to first line in paediatric Crohn's
Acting PBAC Chair tells Senate Estimates that "sponsors are just not commercially enticed" to paediatric populations
Pipeline & Intellectual Property
Six-way legal stoush over $47.5M market
J&J has started proceedings to prevent four companies from launching generic versions of one of its drugs, but a fifth decided it also wanted to get involved
Regulatory & Reimbursement
Big names on NZ's November PTAC meeting
The advisory committee will consider drugs for recommendation to Pharmac for funding medicines
Jobs
Popular
MA lands its 50th member
A new member of Medicines Australia has seen the ranks of the industry organisation swell to 50
Leadership & People
Ex-Aussie GM lands top new role
Less than three years after leaving Australia, this leader who spent five years heading the ANZ team has won another promotion
Industry & Companies
Top pharma employers as voted by staff
Twelve pharmas made the Top 20 science-focused companies to work for list, voted in by the people who work there. See who made the cut
Pipeline & Intellectual Property
CEO stands by takeover despite US$1.9B hit
Insists the phase 3 fail of one of the deal's key assets is just a “bump” for the company and the price of pioneering science
Pipeline & Intellectual Property
Astellas bets $1.89B on Aussie drug
Astellas Pharma has agreed to pay up to $1.89 billion for rights to develop and commercialise a pre-clinical immuno-oncology candidate
Government & Policy
Dept boasts faster medicines access
Annual Report hails 100 per cent strike rate on six-months-to-listing target but the fine print reveals the numbers don't tell the full story
Pipeline & Intellectual Property
Cancer drug's 'unprecedented' trial results
Slashes the risk of death by 58% in this lung cancer patient cohort, with the company describing the findings as a watershed moment in the management of the disease
Regulatory & Reimbursement
Action urged on 'dangerously under-recognised' disease
Boehringer has launched a report to increase public awareness of this disease and exhort government action
Industry & Companies
Aussie repurposer swaps shares for NZ start-up
The move gives access to a repurposed treatment for patients with multiple sclerosis, with the buy raising capital to fund the drug's trial
- Jobs & Workplace Ex-BMS exec wins Aussie Country Lead role
- Industry & Companies Is pharma finally in a good mood?
- Industry & Companies CSL grilled by many cooks
- Government & Policy Butler talks security in the wake of Haines attack
- Leadership & People Company announces another leadership change
- Leadership & People Pharma exec shares life lessons after horror bus crash
- Regulatory & Reimbursement Four pharmas start run for Govt funding
- Jobs & Workplace Farewells dominate Aussie pharma job moves
- Pipeline & Intellectual Property Secret data leak, landmark results... then a share tumble
- Industry & Companies Astellas turns up the heat on politicians